Skip to content

Earnings yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.9%+1.6pp
Myriad Genetics logo
Myriad GeneticsMYGN
-95%-112pp
Labcorp Holdings logo
Labcorp HoldingsLH
4.3%+0.5pp
Quest Diagnostics logo
Quest DiagnosticsDGX
4.8%0.0pp
NeoGenomics logo
NeoGenomicsNEO
-10.3%+16.7pp
Natera, Inc. logo
Natera, Inc.NTRA
-1.4%0.0pp

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Calculated from Fulgent Genetics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s earnings yield?
Fulgent Genetics, Inc. (FLGT) reported earnings yield of -14.9% in Q1 2026.
How has Fulgent Genetics, Inc.'s earnings yield changed year-over-year?
Fulgent Genetics, Inc.'s earnings yield decreased by 90.1% year-over-year, from -7.8% to -14.9%.
What is the long-term trend for Fulgent Genetics, Inc.'s earnings yield?
Over 5 years (2020 to 2025), Fulgent Genetics, Inc.'s earnings yield has grown at a -11.6% compound annual growth rate (CAGR), from 13.8% to -7.5%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.